Humanigen Inc (fka HGENQ)

[ohm20]

I see where they mention CRP < 150. Since it's not an inclusion/exclusion criteria all ordinal scale 7 patients are thrown out of primary endpoint consideration which makes the patient population smaller. Then consider the number at ordinal scale 5 and especially ordinal scale 6 that are over CRP > 150 that might leave a small enough population that there's no way it hits a statistically significant p value.

Bur as the NIH says -

The goal is not to determine clear statistical significance for an intervention, but rather to determine which products have clinical data suggestive of efficacy and should be moved quickly into larger studies.

So when do you expect HGEN to start it's own new phase 3?